Cancer Crosslinks 2016 on January 14 offers you an exciting program with international keynote speakers who made and make major contributions to advance immunotherapies against cancer. Already more than 120 delegates have signed up, but we have room for many more in the Kaare Norum Auditorium at Oslo Cancer Cluster Innovation Park. The conference is sponsored by BMS and Janssen.
The main theme for Cancer Crosslinks 2016 is: «The transversal impact of new treatments in Oncology and Hematology: tumor microenvironment, novel concepts, combinations and study design».
Some program highlights:
- Professor Gordon Freeman, Dana-Farber Cancer Institute and Harvard Medical School, is one of the key persons behind today’s PD-1/ PD-L1 inhibitors. He will share his perspectives on PD-1 cancer immunotherapy. His talk will be complemented by case studies from Norway illustrating the broad impact of immune checkpoint inhibitors for a variety of cancers
- Professor Renier Brentjens, Memorial Sloan-Kettering Cancer Center, will shift the focus to hematological cancers and discuss the advancement of recombinant T-cell technologies including CAR-T-cell approaches for different indications. Norwegian experts will complement his talk with updates on novel immuno-oncology approaches being developed at UiO and OUS
- Stefani Spranger from Professor Tom Gajewski’s lab, University of Chicago will provide the latest insights into the role of T-cell inflammed versus non-inflammed tumor microenvironment for immunotherapy
- Last, but not least: a Norwegian patient will share his perspectives on the importance of novel cancer therapies
Participants working at hospitals and/or academic reserach centres whom have no sources for funding the participation will get flight or train ticket covered. How ever we do not cover local transportation to / from the airport. Flight or train tickets may be ordered by connecting to travel agency Berg-Hansen on e-mail: firstname.lastname@example.org or phone 08050 between 08.00-17.00. The reference code is «OCC».